Michael Zahalsky
Urology · Coral Springs, FLNPI 1801864137
Payments from drug & device makers
Across 235 payments — averaging $63.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Axonics, Inc.$498
- Coloplast$488
- Aytu Biopharma, Inc.$487
- Endo Pharmaceuticals Inc.$474
- Astellas Pharma US Inc$400
- plus $3K from 31 others
What the payments were for
- Consulting fees$2,60017%
- Speaking & faculty fees$6,58044%
- Food & beverage$5,60337%
- Education$2201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 42 | $10,154 |
| Axonics, Inc. | 14 | $498 |
| Coloplast | 12 | $488 |
| Aytu Biopharma, Inc. | 43 | $487 |
| Endo Pharmaceuticals Inc. | 21 | $474 |
| Astellas Pharma US Inc | 18 | $400 |
| Procept Biorobotics Corporation | 4 | $354 |
| Teleflex LLC | 3 | $291 |
| Antares Pharma, Inc. | 9 | $206 |
| Olympus America Inc. | 6 | $206 |
| Johnson & Johnson | 7 | $146 |
| Medtronic | 1 | $131 |
| Mission Pharmacal Company | 7 | $130 |
| Myovant Sciences Inc. | 5 | $120 |
| Halozyme Inc | 5 | $97 |
| Biotissue Holdings Inc. | 2 | $96 |
| Tolmar, Inc. | 4 | $72 |
| Sumitomo Pharma America, Inc. | 3 | $67 |
| Ferring Pharmaceuticals Inc. | 4 | $65 |
| Dendreon Pharmaceuticals LLC | 2 | $54 |
| AstraZeneca | 2 | $46 |
| Blue Earth Diagnostics | 2 | $43 |
| Ambu Inc. | 3 | $43 |
| Rigicon,inc. | 1 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Metuchen Pharmaceuticals | 2 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| Acerus Pharmaceuticals Corporation | 1 | $28 |
| Pfizer | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Biocompatibles, Inc. | 1 | $23 |
| Urogen Pharma, Inc. | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $21 |
| Endo USA, Inc. | 1 | $17 |
| Coopersurgical, Inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| Rochester Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZUM$9,282
- TITAN$280
- AquaBeam Robotic System$268
- UroLift$174
- INTERSTIM$131
- iTIND System$123
- Axonics$115
- SpaceOAR VUE System - 10mL$109
How this compares
$15,003 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrelstarTriptorelin Pamoate | 19 | $47,813 |
| MyrbetriqMirabegron | 49 | $30,369 |
| GemtesaVibegron | 34 | $20,424 |
| Testosterone | 62 | $9,010 |
| XyostedTestosterone Enanthate | 11 | $6,793 |
| Tadalafil | 42 | $4,213 |
| Solifenacin Succinate | 23 | $3,797 |
| Testosterone Cypionate | 104 | $3,548 |
| Estradiol | 23 | $2,661 |
| Finasteride | 218 | $2,032 |
| Tamsulosin Hcl | 170 | $1,750 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 95 | $1,502 |
| Silodosin | 14 | $1,230 |
| Bethanechol Chloride | 17 | $1,011 |
| Dutasteride | 13 | $487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Verity Pharmaceuticals Inc.Trelstar | $24 | $47,81319 claims |
| Astellas Pharma US IncMyrbetriq | $400 | $30,36949 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $67 | $20,42434 claims |
| Antares Pharma, Inc.Xyosted | $206 | $6,79311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.
Other urology in Coral Springs
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
- Craig HermanPompano Beach$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.